Coden: Ijpnl6 Method Development and Validation for the Simultaneous Estimation of Hydrochlorothiazide and Olmesartan Medoxomil by Rp-hplc in Pharmaceutical Dosage Form

A simple, accurate and precised method was developed for the simultaneous estimation of hydrochlorthiazide and olmesartan medoxomil in formulation by RP-HPLC method. Buffer in this method was 0.01N Na2HPO4 of pH 4 used with the combination of acetonitrile in the ratio of 45:55 as mobile phase. 10μl of sample was injected and the mobile phase was run for 7min with flow rate of 1ml/min through BDS 250mm column maintained at 30°C. Wavelength optimized was 257nm. Hydrochlorthiazide and olmesartan were eluted with good resolution of 7.11. Retention times of hydrochlorthiazide and olmesartan were 2.4min and 3.8min respectively. Other system suitability parameters like tailing factor and plate count were within the limits. According to the ICH guidelines this method was validated. There was no placebo interference observed resulting that this method was specific, %RSD obtained for hydrochlorthiazide and olmesartan were 0.6% and 0.7%. On plotting the linearity graph for hydrochlorthiazide and olmesartan linearity equations obtained were y = 12341x + 864.8 and y = 11251x + 1599 respectively. Correlation coefficient was 0.999. % Average recovery was calculate and fount to be 100.05% for hydrochlorthiazide and 100.02% for olmesartan. % Labled amount of both drugs were found to be 99.77% and 99.96% for hydrochlorthiazide and olmesartan. The developed method was validated as per ICH guidelines. As run time was decreased this is economical and simple method that can be used in the regular analysis.